From: Alzheimer’s disease prevention: from risk factors to early intervention
DIAN-TU | API-ADAD | A4 | TOMMORROW | API-GENERATION | EARLY | |
---|---|---|---|---|---|---|
Estimated enrolment | 210 | 300 | 1150 | 3494 | 1340 | 1650 |
Target population/specific characteristics | Autosomal dominant Alzheimer’s disease (ADAD) mutation carriers or persons that have a 50% chance of carrying an ADAD mutation | Membership in PSEN1 E280A mutation carrier kindred | Cognitively normal, positive brain amyloid PET | Cognitively normal with genetic risk (TOMM40 and APOE genotype) | Cognitively normal APOE-ε4 homozygous | Cognitively normal positive amyloid |
Age | 18–80 years | 30–60 years | 65–85 years | 65–83 years | 60–75 years | 60–85 years |
Phase | Phase II/III | Phase II | Phase III | Phase III | Phase II/III | Phase II/III |
Compound | Gantenerumab Solanezumab | Crenezumab | Solanezumab | Pioglitazone | CAD106 CNP520 | JNJ-54861911 |
Mechanism | Anti-Aβ antibodies | Anti-Aβ antibody | Anti-Aβ antibody | PPAR-γ agonist | Aβ vaccine BACE inhibitor | BACE inhibitor |
Status | Ongoing, not recruiting | Active, not recruiting | Recruiting | Active, not recruiting | Recruiting | Recruiting |
Primary outcome | Composite Cognitive Test Score | Composite Cognitive Test Score | Composite Cognitive Test Score | Time to diagnosis of mild cognitive impairment (MCI) due to AD | Time to diagnosis of MCI or dementia due to AD Composite Cognitive Test Score | Composite Cognitive Test Score |
Study duration | 4 years | 5 years | 3 years | 5 years | 5 years | 4.5 years |
Trial identifier | NCT01760005 | NCT01998841 | NCT02008357 | NCT01931566 | NCT02565511 | NCT02569398 |
Expected completion | December 2019 | September 2020 | October 2020 | July 2019 | August 2023 | May 2023 |